Transgene: 100% Relapse-Free Survival, Yet Cash Burn Accelerates by 38%
French biotech company Transgene raised 144 million euros in December 2025 (105 million through private placement and 39 million through debt conversion), bringing its cash reserves to 111.9 million euros as of December 31. This financial base should enable it to continue the development of its flagship candidate TG4050 until early 2028. A major asset, but to be taken with caution: the annual cash burn jumped to 38.2 million euros in 2025, which is 38% more than in 2024.
Clinical Results and Financial Challenges
The clinical results are robust. TG4050, Transgene's personalized therapeutic vaccine, achieved 100% relapse-free survival after at least two years of follow-up in patients with head and neck cancer treated adjuvantly, with a median follow-up of 30 months. All Phase 1 study objectives were met, including safety and tolerability. Translational data confirm durable and specific immune responses to neoantigens. However, financially, the situation has worsened: the net loss stood at 37.5 million euros in 2025, compared to 34.0 million euros in 2024. Operational revenues (7.2 million euros, including 6.7 million from research tax credit) remain marginal compared to R&D expenditures, which amounted to 33.9 million euros.
Cash Burn Rate Raises Concerns
Beyond the annual figures, it is the pace of cash consumption that raises concerns. In 2025, Transgene burned through 38.2 million euros of cash, 10.5 million more than in 2024 — a 38% increase in one year. This consumption reflects the intensification of clinical trials: the randomization of Phase 2 patients for TG4050 is nearly complete, and the company is also preparing a new Phase 1 trial for a second indication in 2026. BT-001, the oncolytic virus under development, also incurs expenses. With 111.9 million euros in cash and an annual burn rate approaching 40 million euros, Transgene theoretically has nearly three years of self-financing — hence the financial guidance until early 2028.
Busy Roadmap for 2026
The 2026 roadmap is packed. Data on three-year relapse-free survival for all Phase 2 patients of TG4050 are expected in the second or third quarter of 2026. Concurrently, Transgene will launch a new Phase 1 trial in a second indication for operable solid tumors. BT-001, presented at ESMO 2025 in combination with MSD's pembrolizumab, showed promising local and distant antitumor activity, justifying further development. Transgene's patented VacDesignR® software optimizes the design of viral vectors. For investors, the stakes are twofold: to clinically validate the potential of personalized therapeutic vaccines before cash reserves become critical, and to demonstrate that the myvac® platform works beyond head and neck cancer. The 2026-2027 window will be decisive.
